This inventor holds 8 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Zealand Pharma A/s. Active years: 2009-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2009-2018
Title: **Yvette Miata Petersen: Innovator in GLP-2 Analogues**
Introduction
Yvette Miata Petersen is an accomplished inventor based in Bagsvaerd, Denmark, with a remarkable portfolio of eight patents. Her work primarily focuses on the development of glucagon-like-peptide-2 (GLP-2) analogs, which hold significant promise for treating stomach and bowel-related disorders.
Latest Patents
Petersen's recent patents include innovative formulations of selective GLP-2 analogues. These analogs feature one or more substitutions compared to the wild-type GLP-2 sequence, which may enhance selectivity between the small intestine and colon, as well as the stomach and colon. More specifically, the analogs disclosed feature notable substitutions at positions 11, 16, 20, 24, and/or 28 of the GLP-2 sequence, along with the potential for further modifications. These advancements are particularly beneficial for the prophylaxis and treatment of various gastrointestinal issues and for mitigating the side effects associated with chemotherapy.
Additionally, her methods of treating stomach or bowel-related disorders focus on administering GLP-2 analogues that exhibit improved in vivo biological activity and chemical stability. This includes substitutions at crucial positions within the GLP-2 sequence, with application strategies tailored for patient selection suited for these treatments.
Career Highlights
Yvette Miata Petersen is primarily associated with Zealand Pharma A/S, a company renowned for its contributions to the development of innovative peptide-based therapies. Her substantial work in therapeutic applications of GLP-2 analogs positions her as a leading figure in this cutting-edge research area.
Collaborations
Among her notable collaborations is Bjarne Due Larsen, a coworker with whom she has worked closely on various projects aimed at advancing GLP-2 therapies. Such collaborations play a critical role in the innovation process, enhancing the efficacy and application of the inventions they develop together.
Conclusion
Yvette Miata Petersen's contributions to the field of GLP-2 analogs not only demonstrate her inventiveness but also her commitment to addressing pressing medical challenges. With a strong foundation of patents and a collaborative spirit, Petersen continues to impact the landscape of therapeutic innovations significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile